You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ph ALL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Lymphoblastic Leukemia Trial (chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 19, 2023

Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease Trial in Tianjin (the usage of Olverembatinib combined with Inotuzumab

Not yet recruiting
  • Ph+ ALL
  • +2 more
  • the usage of Olverembatinib combined with Inotuzumab Ozogamicin
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital, Chinese Acade
Oct 30, 2022

Ph+ ALL Trial in China (Olverembatinib, Imatinib)

Recruiting
  • Ph+ ALL
  • Chongqing, Chongqing, China
  • +8 more
Sep 22, 2023

Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib)

Not yet recruiting
  • Philadelphia-Positive ALL
  • Suzhou, Jiangsu, China
    First Affiliated Hospital of Soochow University
Jul 1, 2023

B Acute Lymphoblastic Leukemia, Ph-Negative ALL, High Risk Acute Lymphoblastic Leukemia Trial (Azacitidine Injection,

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Azacitidine Injection
  • +2 more
  • (no location specified)
Oct 15, 2023

Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib combined with chemo)

Not yet recruiting
  • Philadelphia-Positive ALL
  • Olverembatinib combined with chemotherapy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Jul 17, 2022

Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed Trial in Czechia (Ponatinib 15 MG Oral Tablet)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, Adult
  • +2 more
  • Ponatinib 15 MG Oral Tablet
  • Brno, Czechia
  • +6 more
Nov 30, 2022

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Tianjin (Olverembatinib, Venetoclax, prednisone)

Recruiting
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Oct 21, 2022

Iclusig PMS in CML or Ph+ALL Patients

Recruiting
  • Chronic Myeloid Leukemia
  • Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
  • Busan, Korea, Republic of
    Kosin University Gaspel Hospital
Sep 16, 2021

Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Trial in Worldwide (ABL001, ABL001 +

Active, not recruiting
  • Chronic Myelogenous Leukemia
  • Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
  • Boston, Massachusetts
  • +18 more
Jan 19, 2023

Acute Lymphoblastic Leukemia, Adult Trial in Caba (Evaluation of survival and toxicities in AYA Ph-negative ALL patients

Recruiting
  • Acute Lymphoblastic Leukemia, Adult
  • Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.
  • Paraná, Entre Ríos, Argentina
  • +1 more
Dec 29, 2022

Acute Lymphoblastic Leukemia Trial in Suzhou (cladribine, cytarabine,venetoclax)

Recruiting
  • Acute Lymphoblastic Leukemia
  • cladribine, cytarabine,venetoclax
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 22, 2022

Acute Leukemia Trial in Tianjin (Flumatinib, Imatinib)

Recruiting
  • Acute Leukemia
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Sep 27, 2021

Acute Lymphoblastic Leukemia (ALL) Trial (Nilotinib)

No longer available
  • Acute Lymphoblastic Leukemia (ALL)
  • (no location specified)
Aug 5, 2022

Acute Lymphocytic Leukemia Trial (Inotuzumab ozogamicin)

Not yet recruiting
  • Acute Lymphocytic Leukemia
  • Inotuzumab ozogamicin
  • (no location specified)
Jul 11, 2022

Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic Trial in Guangzhou (Chidamide, Dasatinib)

Recruiting
  • Leukemia
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Hematology, Nanfang Hospital
Jun 28, 2022

Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL, Newly Diagnosed Trial in Czechia (Blinatumomab)

Active, not recruiting
  • Lymphoblastic Leukemia, Acute, Adult
  • +2 more
  • Brno, Czechia
  • +4 more
Aug 3, 2022

Philadelphia Positive Acute Lymphoblastic Leukemia Trial in Germany (Dasatinib)

Completed
  • Philadelphia Positive Acute Lymphoblastic Leukemia
  • Stuttgart, Baden-Württemberg, Germany
  • +21 more
Jan 10, 2022

Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia Trial in

Not yet recruiting
  • Lymphoblastic Leukemia, Acute, Childhood
  • +3 more
  • Olverembatinib, APG-2575, Dexamethasone
  • Hefei, Anhui, China
  • +3 more
Aug 8, 2022

Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL Trial in Italy (Ponatinib

Recruiting
  • Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
  • +2 more
  • Ponatinib + Blinatumomab
  • Chemotherapy + Imatinib
  • Ascoli Piceno, Italy
  • +14 more
Jan 3, 2022

Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia Trial in Chicago (Inotuzumab ozogamicin,

Recruiting
  • Lymphoblastic Leukemia
  • +2 more
  • Inotuzumab ozogamicin
  • +7 more
  • Chicago, Illinois
    University of Chicago Medical Center
May 16, 2022

B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Chicago, Illinois
  • +5 more
Dec 27, 2021

Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse Trial in Italy (Ponatinib)

Recruiting
  • Philadelphia-Positive ALL
  • Acute Lymphoblastic Leukemia, in Relapse
  • Ancona, Italy
  • +21 more
Jan 3, 2022

B Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab)

Recruiting
  • B Acute Lymphoblastic Leukemia
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Nov 1, 2022

Lymphoma Leukemia Trial in Minneapolis (allogeneic CAR19 regulatory T cells (CAR19-tTreg))

Not yet recruiting
  • Lymphoma Leukemia
  • allogeneic CAR19 regulatory T cells (CAR19-tTreg)
  • +2 more
  • Minneapolis, Minnesota
    Masonic Cancer Center - University of Minnesota
Dec 6, 2022